Race Treatment and Cardiovascular Health: A Study of Men with Prostate Cancer
Abstract
As more men live with their prostate cancer, they face increased risk of cardiovascular disease (CVD). This risk is intensified by treatment type, in particular androgen deprivation therapy (ADT). There is a paucity of data exploring the risk of CVD among minority men with prostate cancer overall or by treatment type. The purpose of this study is to examine race-specific CVD risk in men with prostate cancer, overall and by treatment type. A total of 2,000 prostate cancer cases (1,000 each African American and Caucasian) have been identified and over 1,200 have been abstracted. Overall, approximately 75% of men had a post-diagnosis lipid profile drawn. However, lipid monitoring was lacking among those who were ever given ADT, predominantly in the Caucasian group, demonstrating a potential gap in CVD risk factor monitoring in a high-risk group. In our population, ADT increased cholesterol levels in both African-American and Caucasian men with prostate cancer, which suggests a need for guidelines for regular screening of men treated with ADT. We are now exploring the role of pre- and post-diagnosis of hypercholesterolemia, use of cholesterol-lowering medications, and the role of additional cardiovascular risk factors (e.g., hypertension, diabetes) on risk of events in this population of African-American and Caucasian prostate cancer cases.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2011
- Accession Number
- ADA555793
Entities
People
- Andrea Cassidy-bushrow
Organizations
- Henry Ford Health